News Article
Jan 27, 2020
ReViral’s Phase 2a RSV Study publication selected as Editor’s Pick in February 2020 issue of ASM's Antimicrobial Agents and Chemotherapy

See full published article: https://aac.asm.org/content/64/2/e01884-19 

A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.